Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

NeoStem (NBS)

NBS RSS Feed
Add NBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator andy e
Search This Board:
Last Post: 10/13/2014 10:19:00 AM - Followers: 96 - Board type: Free - Posts Today: 0

NeoStem, Inc (NBS) 


 

 

 

http://www.neostem.com

 

 

 

 

Company Information:

420 Lexington Avenue
Suite 450

New York, New York 10170

Telephone: 212-584-4180
Fax: 646-514-7787

 

CIK:  0000320017

 

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
 
Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
 
Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services.
 
Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing our own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents our most clinically advanced therapeutic product candidate and enrollment for our Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (“AMI”) patients commenced in 2012. We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and position the Company to capture a meaningful share of the worldwide AMI market.
 
Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. We plan to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat type 1 diabetes, graft vs. host disease, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection and expect to file an Investigational New Drug Application ("IND") with the FDA in 2013 and commence human clinical studies in one of these disease conditions thereafter.
 
Our pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology platform for which we expect to file an IND with the FDA in late 2013 or early 2014 to initiate an National Institutes of Health ("NIH") funded human clinical studies treating periodontitis with VSELs TM . We are also working on a Department of Defense funded study of VSELs TM and mesenchymal stem cells for the treatment of chronic wounds.
 
NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level allowing our developing a network to scale rapidly if the demand grows.
 
We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.

 




 

Management:   http://www.neostem.com/leadership/robin-l-smith.html

 

 

Feature Stories:   http://www.neostem.com/feature-stories/

 

 

Recent News:   http://www.neostem.com/media/

 

http://finance.yahoo.com/q/h?s=NBS+Headlines

 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000320017&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004

 


 

 

Investor Relations:

Robin L. Smith
Phone: +1 (212) 584-4174
email: rsmith@neostem.com


 

 

 

 

 

 

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#1634   I just know what I see watching these expediter13 10/13/14 10:19:00 AM
#1633   I dont own it... expediter13 10/13/14 10:11:54 AM
#1632   2.5 mil short, steady since July brownsfan407 10/09/14 05:57:33 PM
#1631   How much do you think we are worth brownsfan407 10/04/14 01:52:11 PM
#1630   I'm always wary of people who talk like Pyrrhonian 10/03/14 07:29:55 PM
#1629   I am not ! They have been working expediter13 10/03/14 11:37:19 AM
#1628   99% failure?! Thanks for not exaggerating.. Pyrrhonian 10/03/14 10:46:06 AM
#1627   I hope no one fails ! EVER ! expediter13 10/03/14 10:40:11 AM
#1626   It's odd to see someone hope so much Pyrrhonian 10/02/14 05:47:56 PM
#1625   LOL. That is backwards, but nice try. They expediter13 10/02/14 08:49:44 AM
#1624   If not positive, down into the $4s. But Pyrrhonian 09/30/14 08:23:19 PM
#1623   I thought they had about 33 million and brownsfan407 09/30/14 06:38:48 PM
#1622   Agreed. You'd dilute now while the price is Pyrrhonian 09/30/14 06:22:22 PM
#1621   If I had any fears of bad numbers, brownsfan407 09/30/14 06:01:37 PM
#1620   Actually, have not even considered the embargo policy: http://newsroom.heart.org Pyrrhonian 09/30/14 10:14:20 AM
#1619   To add to this, there is one additional possibility. Pyrrhonian 09/30/14 09:25:47 AM
#1618   "The loan matures in September 2018 and the Pyrrhonian 09/29/14 06:50:51 PM
#1617   Here comes the big fall... no one borrows expediter13 09/29/14 01:58:37 PM
#1616   LOL...it is what it is!, can't win without andy e 09/26/14 06:03:24 PM
#1615   Suker article... we seen the same stuff each expediter13 09/26/14 04:47:48 PM
#1614   NeoStem: Timing Is Everything andy e 09/20/14 09:22:56 AM
#1613   WAITING, WAITING AND MORE WAITING WHILE ALL IS whirlybird 08/16/14 02:53:29 PM
#1612   Current Report Filing (8-k) andy e 08/07/14 05:03:57 PM
#1611   Im In lots of upside stockmarkot 06/27/14 09:07:42 PM
#1610   NeoStem Set to Join Multiple Russell Indexes andy e 06/23/14 05:59:37 PM
#1609   Nice news out this morning on Neostem....love the common_cents 06/16/14 07:36:30 AM
#1608   Securities Registration Statement (simplified Form) (s-3) andy e 06/12/14 05:42:31 PM
#1607   Here comes the dilution... andy e 06/03/14 06:25:10 PM
#1606   Any idea of the duration of the trial? imtheking 06/02/14 06:55:32 PM
#1605   Aegis Capital price target is $21.00 KarinCA 06/02/14 04:25:31 PM
#1604   Great news here StickyStock 05/29/14 08:50:28 AM
#1603   NeoStem Expands Patent Portfolio With Grant of Two andy e 05/19/14 12:43:59 PM
#1602   NeoStem Announces Licensing Agreement and Plans to Begin andy e 05/13/14 05:28:22 PM
#1601   Haha agreed StickyStock 05/13/14 05:27:23 PM
#1600   Less frustrating here whirlybird 05/13/14 03:44:08 PM
#1599   Frustrating here StickyStock 04/30/14 02:29:44 PM
#1598   This title is crazy. There is not positive ajnapower 04/30/14 01:09:36 PM
#1597   NeoStem's Subsidiary, Progenitor Cell Therapy Enters Into a andy e 04/30/14 10:16:53 AM
#1596   Two P3 trials using PCT stem cells are whirlybird 04/29/14 01:29:23 PM
#1595   This thing needs to get going StickyStock 04/23/14 03:50:39 PM
#1594   Need for financing is obvious, BUT -- whirlybird 04/21/14 12:23:29 PM
#1593   MR. FEURSTEIN IS MISLEADING whirlybird 04/17/14 05:26:58 PM
#1592   How many cures? whirlybird 04/17/14 10:34:41 AM
#1591   Is Financing a Problem? whirlybird 04/16/14 11:44:54 AM
#1590   NeoStem Announces Definitive Agreement to Acquire California Stem andy e 04/14/14 05:53:53 PM
#1589   A P3 SPA and fast track approved FDA whirlybird 04/14/14 10:46:07 AM
#1588   Hugeeeeeeeee StickyStock 04/14/14 07:56:41 AM
#1587   NeoStem Announces Conference Call and Webcast andy e 04/12/14 11:46:00 AM
#1586   New seeking alpha article. andy e 04/06/14 09:25:56 AM
#1585   Seems possible acquisition of Neostem by Baxter? ajnapower 04/03/14 06:19:22 PM
PostSubject